Needham Maintains Buy Rating for Avadel Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Needham has reaffirmed its Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and increased its price target from $19.00 to $20.00. Despite this, AVDL's shares have fallen 1.34% in the last 24 hours to $14.01. The new price target suggests a potential upside of 42.76%. Avadel is a specialty pharmaceutical company focusing on controlled-release products and markets several products in the U.S.
December 20, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham maintains a Buy rating on Avadel Pharmaceuticals and raises the price target to $20, suggesting a significant upside from the current price.
The reaffirmation of a Buy rating and an increased price target by a reputable analyst firm like Needham is typically a positive signal for investors, suggesting confidence in the company's future performance. This could lead to increased investor interest and a potential rise in AVDL's stock price in the short term, despite the recent dip.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100